New radiation combo shows promise in tough brain cancer battle

NCT ID NCT07100730

Recruiting now Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 14, 2026 · Updated 18 times

Summary

This study tests a new drug, TLX101-Tx, which delivers radiation directly to glioblastoma cells, combined with standard chemotherapy (lomustine) in 50 adults whose brain cancer has returned after initial treatment. The goal is to see if the combination helps control the tumor better than chemotherapy alone. Participants are randomly assigned to receive either the combination or standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Health
RECRUITING

Melbourne, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Gold Coast University Hospital
RECRUITING

Gold Coast, Queensland, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Johannes Kepler University
RECRUITING

Linz, Austria
UMC Utrecht
RECRUITING

Utrecht, Netherlands

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA GLIOBLASTOMA GLIOBLASTOMA (GBM) GLIOBLASTOMA MULTIFORM GLIOBLASTOMA MULTIFORME (GBM) WHO GRADE IV GLIOBLASTOMA MULTIFORME, ADULT GLIOBLASTOMA MULTIFORME, ADULT NEOPLASTIC DISEASE